Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) shares were down 0.1% during mid-day trading on Monday . The stock traded as low as $67.6350 and last traded at $67.99. Approximately 184,471 shares traded hands during mid-day trading, a decline of 3% from the average daily volume of 189,291 shares. The stock had previously closed at $68.08.
Gemini Therapeutics Price Performance
The company’s 50-day moving average is $68.42 and its 200-day moving average is $72.10. The firm has a market capitalization of $3.03 billion, a price-to-earnings ratio of -69.83 and a beta of -0.12.
About Gemini Therapeutics
Gemini Therapeutics (NASDAQ:GMTX) is a clinical‐stage biotechnology company focused on the discovery and development of integrin‐targeting therapies for fibrotic diseases. Leveraging a proprietary antibody discovery platform, Gemini identifies and optimizes highly selective inhibitors of integrin subunits that play a key role in activating transforming growth factor‐β (TGF-β), a central driver of tissue fibrosis. The company’s approach is designed to block fibrotic signaling at its source, potentially offering improved safety and efficacy profiles compared with broader anti‐fibrotic agents.
Gemini’s lead programs are directed toward chronic kidney disease and idiopathic pulmonary fibrosis, two areas with significant unmet medical need and limited treatment options.
Featured Articles
- Five stocks we like better than Gemini Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
